We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

8002:TSEMarubeni Corporation Analysis

Data as of 2026-06-17 - not real-time

¥4,949.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Marubeni Corp (8002.T) is trading at ¥4,949, comfortably above its technical support of ¥4,713 but below the 20‑day SMA of ¥5,045, indicating a modest upside cushion. The RSI of 41 signals a neutral stance without overbought pressure, while the MACD histogram (+19) and bullish MACD signal suggest emerging positive momentum. Valuation metrics are compelling: a trailing PE of ~15 is less than half the industry average of 31, and the price‑to‑book of 1.86 reflects modest premium over book value. The DCF‑derived fair value of ¥276 versus the current price underscores a significant discount, positioning the stock as undervalued. Fundamentals remain solid with a 1.1% revenue growth, healthy operating cash flow of ¥535 bn, and a low debt‑to‑equity ratio of 53, though margins are modest (gross 14%, operating 3%). Risk metrics are favorable – beta around 0.33 indicates low systematic risk, and despite a 30‑day volatility of 36%, the stock’s massive market cap and decreasing volume suggest ample liquidity. Overall, the blend of attractive valuation, stable cash generation, and low beta supports a buy recommendation across horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support but below short‑term moving averages
  • Neutral RSI and bullish MACD histogram
  • Low beta reducing near‑term market sensitivity

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation discount to DCF fair value
  • Strong cash flow generation supporting earnings stability
  • Undervalued PE relative to industry peers

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Diversified conglomerate model providing resilience across cycles
  • Low systematic risk and solid balance sheet
  • Attractive long‑term upside potential given current discount

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin6.58%
P/E Ratio15.0
ROE13.50%
ROA1.63%
Debt/Equity53.39
P/B Ratio1.9
Op. Cash Flow¥535.4B
Free Cash Flow¥165.9B
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI40.9
Support¥4,713.00
Resistance¥5,477.00
MA 20¥5,045.55
MA 50¥5,520.14
MA 200¥4,741.22
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value¥275.67
Target Price¥6,146.15
Upside/Downside24.19%
GradeUndervalued
TypeValue

Risk Assessment

Beta0.34
Volatility36.00%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.